RZLT vs. CLRB, ABEO, IMUX, ADAG, FGEN, CRVS, CTXR, PMVP, RLMD, and ACET
Should you be buying Rezolute stock or one of its competitors? The main competitors of Rezolute include Cellectar Biosciences (CLRB), Abeona Therapeutics (ABEO), Immunic (IMUX), Adagene (ADAG), FibroGen (FGEN), Corvus Pharmaceuticals (CRVS), Citius Pharmaceuticals (CTXR), PMV Pharmaceuticals (PMVP), Relmada Therapeutics (RLMD), and Adicet Bio (ACET). These companies are all part of the "pharmaceutical preparations" industry.
Cellectar Biosciences (NASDAQ:CLRB) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership, community ranking and analyst recommendations.
In the previous week, Cellectar Biosciences had 6 more articles in the media than Rezolute. MarketBeat recorded 17 mentions for Cellectar Biosciences and 11 mentions for Rezolute. Rezolute's average media sentiment score of 0.61 beat Cellectar Biosciences' score of 0.27 indicating that Cellectar Biosciences is being referred to more favorably in the media.
Cellectar Biosciences presently has a consensus price target of $20.00, indicating a potential upside of 500.60%. Rezolute has a consensus price target of $8.80, indicating a potential upside of 243.75%. Given Rezolute's higher possible upside, equities research analysts clearly believe Cellectar Biosciences is more favorable than Rezolute.
Cellectar Biosciences received 185 more outperform votes than Rezolute when rated by MarketBeat users. However, 75.34% of users gave Rezolute an outperform vote while only 56.07% of users gave Cellectar Biosciences an outperform vote.
Rezolute is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
Cellectar Biosciences' return on equity of -51.81% beat Rezolute's return on equity.
Cellectar Biosciences has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Rezolute has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.
16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 4.6% of Cellectar Biosciences shares are owned by insiders. Comparatively, 20.8% of Rezolute shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Rezolute beats Cellectar Biosciences on 8 of the 14 factors compared between the two stocks.
Get Rezolute News Delivered to You Automatically
Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rezolute Competitors List
Related Companies and Tools
